Spyre Therapeutics, Inc. SYRE
85.69
(1.40)
(1.61%)
as of 25 Sep
- Market cap
- $7.7B
- P/E
- 0.0×
Follow SYRE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
10.51 | 12.89 | 8.71 | 18.09 | |
Current Ratio |
10.90 | 13.25 | 8.97 | 18.53 | |
Net Debt/EBITDA |
8.55 | 13.23 | 16.25 | 27.51 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
3.32 | 0.71 | 0.83 | 1.93 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.61) | (0.70) | (0.73) | (0.82) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.61) | (0.70) | (0.73) | (0.82) | |
Cash per Share |
8.05 | 11.81 | 9.44 | 13.52 | |
Shareholders Equity per Share |
7.53 | 11.17 | 8.54 | 13.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.53 | 11.17 | 8.54 | 13.00 | |
Free Cash Flow |
(37.12) | (44.58) | (57.37) | (69.88) | |
Working Capital |
458.33 | 719.10 | 678.79 | 1,109.70 | |
Net Current Asset Value |
455.10 | 715.24 | 670.81 | 1,101.14 | |
EV/EBIT |
— | — | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
| Other line items | |||||
Average Payables |
6.31 | 4.79 | 4.69 | 4.72 | |
Average Assets |
462.85 | 693.13 | 666.87 | 855.92 | |
Average Common Equity |
235.43 | 460.70 | 420.89 | 627.33 |
Columns are period end dates